<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01043419</url>
  </required_header>
  <id_info>
    <org_study_id>ALS-8-09-A-101</org_study_id>
    <secondary_id>Eudract N°2009-012449-48</secondary_id>
    <nct_id>NCT01043419</nct_id>
  </id_info>
  <brief_title>Sympathetic Neural Outflow During Xenon Anesthesia in Humans</brief_title>
  <official_title>Sympathetic Neural Outflow During Xenon Anesthesia in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Air Liquide Santé International</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Air Liquide Santé International</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the hypothesis that sympathetic neural outflow to
      muscles as well as a sympathetic baroreflexes are not altered during xenon anesthesia in
      Healthy Volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives for this study :

        -  Main Objective : Influence of Xenon anesthesia on Sympathetic Nervous Activity

        -  Secondary Objectives : Security under LENOXe™ (xénon 100 % v/v) anesthesia
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Muscle Sympathetic Activity (MSA)and Baroreflex reagibility under Xenon Anesthesia in comparison to awake</measure>
    <time_frame>30 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arterial blood pressure, Heart frequency, Arterial O2 and CO2 Saturation,Skin conductance,Concentration of plasma catecholamines, Angiotensin &amp; Renin under Xenon Anesthesia in comparison to awake</measure>
    <time_frame>In continuous during 30 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Sympathetic Nervous System</condition>
  <arm_group>
    <arm_group_label>LENOXe™ (xénon 100 % v/v)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Influence of LENOXe™ (xénon 100 % v/v) anesthesia on Sympathetic Nervous Activity and Security under LENOXe™ (xénon 100 % v/v) anesthesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>xenon</intervention_name>
    <description>Inhalational gas; dose allowed max.70 Vol.% in 30 % oxygen; the duration of the treatment will be to 30 minutes</description>
    <arm_group_label>LENOXe™ (xénon 100 % v/v)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers &gt; 18 years and &lt; 65 years of age

          -  ASA physical status I

          -  Legal competence

          -  for whom the consent form has been signed

        Exclusion Criteria:

          -  Healthy volunteers &lt; 18 years and &gt; 65 years of age

          -  Pregnancy, lactation period or missing secure anticonvulsive therapy

          -  Missing legal competence

          -  Participation in other clinical trials

          -  Contraindications as mentioned on §4.3 of the SPCs of LENOXe™ (xénon 100 % v/v)

          -  Any medication especially of Sildenafil (Viagra®) or other potency remedy

          -  Existing relationship of dependency to the sponsor or the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter KIENBAUM, PD Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anesthesiology, University Hospital Duesseldorf, Moorenstrasse 5, D-40225 Duesseldorf</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Anesthesiology; University Hospital of Duesseldorf; Moorenstrasse 5</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2010</study_first_submitted>
  <study_first_submitted_qc>January 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2010</study_first_posted>
  <last_update_submitted>June 29, 2010</last_update_submitted>
  <last_update_submitted_qc>June 29, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2010</last_update_posted>
  <responsible_party>
    <name_title>Catherine Billoët, MD</name_title>
    <organization>Air Liquide Santé International</organization>
  </responsible_party>
  <keyword>Xenon Anesthesia</keyword>
  <keyword>LENOXe™ (xénon 100 % v/v) anesthesia</keyword>
  <keyword>Muscle Sympathetic Activity</keyword>
  <keyword>Baroreflex reagibility</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Xenon</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

